Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension

Once perceived as a disorder treated by vasodilation, pulmonary artery hypertension (PAH) has emerged as a pulmonary vascular disease with severe endothelial cell dysfunction. In the absence of a cure, many studies seek to understand the detailed mechanisms of EC regulation to potentially create mor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jaylen Hudson, Laszlo Farkas
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	pulmonary arterial hypertension endothelial cell endothelial dysfunction inflammation epigenetic regulation Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/1d9b3eba1f3641329b062bb9c812a124
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1d9b3eba1f3641329b062bb9c812a124
record_format	dspace
spelling	oai:doaj.org-article:1d9b3eba1f3641329b062bb9c812a1242021-11-25T17:53:23ZEpigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension10.3390/ijms2222120981422-00671661-6596https://doaj.org/article/1d9b3eba1f3641329b062bb9c812a1242021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/22/12098https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Once perceived as a disorder treated by vasodilation, pulmonary artery hypertension (PAH) has emerged as a pulmonary vascular disease with severe endothelial cell dysfunction. In the absence of a cure, many studies seek to understand the detailed mechanisms of EC regulation to potentially create more therapeutic options for PAH. Endothelial dysfunction is characterized by complex phenotypic changes including unchecked proliferation, apoptosis-resistance, enhanced inflammatory signaling and metabolic reprogramming. Recent studies have highlighted the role of epigenetic modifications leading to pro-inflammatory response pathways, endothelial dysfunction, and the progression of PAH. This review summarizes the existing literature on epigenetic mechanisms such as DNA methylation, histone modifications, and non-coding RNAs, which can lead to aberrant endothelial function. Our goal is to develop a conceptual framework for immune dysregulation and epigenetic changes in endothelial cells in the context of PAH. These studies as well as others may lead to advances in therapeutics to treat this devastating disease.Jaylen HudsonLaszlo FarkasMDPI AGarticlepulmonary arterial hypertensionendothelial cellendothelial dysfunctioninflammationepigenetic regulationBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 12098, p 12098 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	pulmonary arterial hypertension endothelial cell endothelial dysfunction inflammation epigenetic regulation Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	pulmonary arterial hypertension endothelial cell endothelial dysfunction inflammation epigenetic regulation Biology (General) QH301-705.5 Chemistry QD1-999 Jaylen Hudson Laszlo Farkas Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension
description	Once perceived as a disorder treated by vasodilation, pulmonary artery hypertension (PAH) has emerged as a pulmonary vascular disease with severe endothelial cell dysfunction. In the absence of a cure, many studies seek to understand the detailed mechanisms of EC regulation to potentially create more therapeutic options for PAH. Endothelial dysfunction is characterized by complex phenotypic changes including unchecked proliferation, apoptosis-resistance, enhanced inflammatory signaling and metabolic reprogramming. Recent studies have highlighted the role of epigenetic modifications leading to pro-inflammatory response pathways, endothelial dysfunction, and the progression of PAH. This review summarizes the existing literature on epigenetic mechanisms such as DNA methylation, histone modifications, and non-coding RNAs, which can lead to aberrant endothelial function. Our goal is to develop a conceptual framework for immune dysregulation and epigenetic changes in endothelial cells in the context of PAH. These studies as well as others may lead to advances in therapeutics to treat this devastating disease.
format	article
author	Jaylen Hudson Laszlo Farkas
author_facet	Jaylen Hudson Laszlo Farkas
author_sort	Jaylen Hudson
title	Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension
title_short	Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension
title_full	Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension
title_fullStr	Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension
title_full_unstemmed	Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension
title_sort	epigenetic regulation of endothelial dysfunction and inflammation in pulmonary arterial hypertension
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/1d9b3eba1f3641329b062bb9c812a124
work_keys_str_mv	AT jaylenhudson epigeneticregulationofendothelialdysfunctionandinflammationinpulmonaryarterialhypertension AT laszlofarkas epigeneticregulationofendothelialdysfunctionandinflammationinpulmonaryarterialhypertension
_version_	1718411849409495040

Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension

Ejemplares similares